Neutralizing Antibody Responses to SARS-CoV-2 in Korean Patients Who Have Recovered from COVID-19
4
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: Neutralizing antibodies (NAbs) have been considered effective in preventing and treating viral infections. However, untilnow, the duration and clinical implications of antibody-mediated nature immunity in Koreans have remained unknown. Therefore, we examined NAbs levels and clinical characteristics in recovered coronavirus disease 2019 (COVID-19) patients. Materials and Methods: Blood samples were collected from 143 adult patients who had been diagnosed with and had recoveredfrom COVID-19 from February to March in 2020 at a tertiary-care university-affiliated hospital in Daegu, Korea. A plaque reductionneutralization test was conducted to analyze NAb titers. Individualized questionnaires were used to identify patient clinical information. Results: The median number of days from symptom onset to the blood collection date was 109.0 (104.0; 115.0). The NAb titersranged from 10 to 2560. The median NAb titer value was 40. Of the 143 patients, 68 (47.6%) patients had NAb titers ≥80, and 31(21.7%) patients had NAb titers ≥160. The higher the age or disease severity, the higher the NAb titer. In univariate logistic regression,statistically significant predictors of high NAb titers (≥80) were age, myalgia, nausea or vomiting, dyspnea, and disease severity(p<0.05). Multivariable logistic regression showed that age ≥50 years (p=0.013) and moderate or higher disease severity (p<0.001)were factors associated with high NAb titers (≥80). None of the patients had reinfection of COVID-19. Conclusion: All recovered patients were found to have NAbs regardless of the NAb titers maintained by natural immunity. Ageand disease severity during COVID-19 infection were associated with high NAb titers.
Abstract
Purpose: Neutralizing antibodies (NAbs) have been considered effective in preventing and treating viral infections. However, untilnow, the duration and clinical implications of antibody-mediated nature immunity in Koreans have remained unknown. Therefore, we examined NAbs levels and clinical characteristics in recovered coronavirus disease 2019 (COVID-19) patients. Materials and Methods: Blood samples were collected from 143 adult patients who had been diagnosed with and had recoveredfrom COVID-19 from February to March in 2020 at a tertiary-care university-affiliated hospital in Daegu, Korea. A plaque reductionneutralization test was conducted to analyze NAb titers. Individualized questionnaires were used to identify patient clinical information. Results: The median number of days from symptom onset to the blood collection date was 109.0 (104.0; 115.0). The NAb titersranged from 10 to 2560. The median NAb titer value was 40. Of the 143 patients, 68 (47.6%) patients had NAb titers ≥80, and 31(21.7%) patients had NAb titers ≥160. The higher the age or disease severity, the higher the NAb titer. In univariate logistic regression,statistically significant predictors of high NAb titers (≥80) were age, myalgia, nausea or vomiting, dyspnea, and disease severity(p<0.05). Multivariable logistic regression showed that age ≥50 years (p=0.013) and moderate or higher disease severity (p<0.001)were factors associated with high NAb titers (≥80). None of the patients had reinfection of COVID-19. Conclusion: All recovered patients were found to have NAbs regardless of the NAb titers maintained by natural immunity. Ageand disease severity during COVID-19 infection were associated with high NAb titers.
참고문헌 (28)
- Duan K, "Effectiveness of convalescent plasma therapy in severe COVID-19 patients", Proc Natl Acad Sci U S A, 117, pp.9490~9496 (2020)
- Shen C, "Treatment of 5critically ill patients with COVID-19 with convalescent plasma", JAMA, 323, pp.1582~1589 (2020)
- Addetia A, "Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate", J Clin Microbiol, 58, pp.e02107~20 (2020)
- Zinkernagel RM, "On natural and artificial vaccinations", Annu Rev Immunol, 21, pp.515~546 (2003)
- Van Griensven J, "Evaluation of convalescent plasma for Ebola virus disease in Guinea", N Engl J Med, 374, pp.33~42 (2016)
- 안진영, "Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea", Journal of Korean Medical Science, 35(14), pp.1~8 (2020), 대한의학회[DOI]
- Liu STH, "Convalescent plasma treatment of severe COVID-19 : a propensity score-matched control study", Nat Med, 26, pp.1708~1713 (2020)
- U.S. Department of Health and Human Services Food and Drug Administration, "Investigational COVID-19 convalescent plasma:guidance for industry", FDA, ~ (2020)
- Garcia-Beltran WF, "COVID-19-neutralizing antibodies predict disease severity and survival", Cell, 184, pp.476~488 (2021)
- Kim Shin-Woo, "Clinical Characteristics and Outcomes of COVID-19 Cohort Patients in Daegu Metropolitan City Outbreak in 2020", Journal of Korean Medical Science, 36(1), pp.1~15 (2021), 대한의학회[DOI]
- Sethuraman N, "Interpreting diagnostic tests for SARS-CoV-2", JAMA, 323, pp.2249~2251 (2020)
- Yahav D, "Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity", Clin Microbiol Infect, 27, pp.315~318 (2021)
- Yu J, "DNA vaccine protection against SARS-CoV-2 in rhesus macaques", Science, 369, pp.806~811 (2020)
- Tian X, "Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody", Emerg Microbes Infect, 9, pp.382~385 (2020)
- Zhou G, "Perspectives on therapeutic neutralizing antibodies against the novel coronavirus SARS-CoV-2", Int J Biol Sci, 16, pp.1718~1723 (2020)
- Liu Z, "Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization", Cell Host Microbe, 29, pp.477~488 (2021)
- Long QX, "Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections", Nat Med, 26, pp.1200~1204 (2020)
- Liu L, "High neutralizing antibody titer in intensive care unit patients with COVID-19", Emerg Microbes Infect, 9, pp.1664~1670 (2020)
- Chen X, "Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19", Signal Transduct Target Ther, 5, pp.180~ (2020)
- Choe PG, "Antibody responses to SARS-CoV-2 at 8 weeks postinfection in asymptomatic patients", Emerg Infect Dis, 26, pp.2484~2487 (2020)
- "Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. 2020.03.30.20047365" (2020)[URL]
- Robbiani DF, "Convergent antibody responses to SARS-CoV-2 in convalescent individuals", Nature, 584, pp.437~442 (2020)
- Seow J, "Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans", Nat Microbiol, 5, pp.1598~1607 (2020)
- Klein SL, "Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population", J Clin Invest, 130, pp.6141~6150 (2020)
- Wu F, "Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in Shanghai, China", JAMA Intern Med, 180, pp.1356~1362 (2020)
- Zhou F, "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study", Lancet, 395, pp.1054~1062 (2020)
- Megan M Sheehan, "Reinfection Rates Among Patients Who Previously Tested Positive for Coronavirus Disease 2019: A Retrospective Cohort Study", Clinical Infectious Diseases, 73(10), pp.1882~1886 (2021), Oxford University Press (OUP)[DOI]
- Kim YI, "Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission", Emerg Microbes Infect, 10, pp.152~160 (2021)